Daptomycin in vitro susceptibility in European Gram-positive clinical isolates

International Journal of Antimicrobial Agents
Ad C FluitDana Milatovic

Abstract

The objective of this study was to determine the activity of daptomycin, a novel lipopeptide, against European Gram-positive isolates (n = 1539). The MIC(90)-values of daptomycin against Staphylococcus aureus isolates was 0.25 mg/L, against Enterococcus faecalis 4 mg/L, against Enterococcus faecium 8 mg/L, 0.25 mg/L against Staphylococcus epidermidis, and 0.25mg/L against Streptococcus pneumoniae. Daptomycin was equally potent against antibiotic-susceptible and resistant strains within a particular species. Based on a breakpoint of 1 mg/L for S. aureus and group A streptococci, all isolates tested were susceptible to daptomycin. Based on a breakpoint of 4 mg/L for vancomcyin-susceptible E. faecalis 99.7% of these isolates were susceptible to daptomycin.

References

Aug 1, 1987·The Journal of Antimicrobial Chemotherapy·J H AndrewD Greenwood
Feb 22, 2001·Antimicrobial Agents and Chemotherapy·A LouieG L Drusano
May 17, 2001·Antimicrobial Agents and Chemotherapy·J A SilvermanT Li
Oct 3, 2001·The Journal of Antimicrobial Chemotherapy·P C FuchsS D Brown
Dec 26, 2001·The Journal of Antimicrobial Chemotherapy·Ralf René ReinertRudolf Lütticken
Feb 28, 2002·The Journal of Antimicrobial Chemotherapy·Peter C FuchsSteven D Brown
Jun 14, 2003·The Journal of Antimicrobial Chemotherapy·S S RichterG V Doern

❮ Previous
Next ❯

Citations

Feb 20, 2010·Annals of Clinical Microbiology and Antimicrobials·Marylene Duah
Feb 4, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Theodoros KelesidisDavid A Pegues
Dec 17, 2008·Scandinavian Journal of Infectious Diseases·Vega A GoedeckeMarcus Hiss
Mar 17, 2007·Scandinavian Journal of Infectious Diseases·Zeina A KanafaniVance G Fowler
Nov 2, 2006·Current Medical Research and Opinion·Javier Garau
Sep 28, 2010·International Journal of Antimicrobial Agents·E BatardG Potel
Sep 9, 2008·International Journal of Antimicrobial Agents·E MalliE Petinaki
Jul 17, 2007·The Journal of Infection·David A EnochJ Andreas Karas
Nov 20, 2014·The Journal of Antimicrobial Chemotherapy·Nicola PrincipiSusanna Esposito
Dec 3, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E Bouza
Feb 12, 2005·The Journal of Antimicrobial Chemotherapy·Judith N SteenbergenFrancis P Tally
Jul 21, 2020·Journal of Medicinal Chemistry·John A KarasTony Velkov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.